|
- Drug-induced Guillain-Barré Syndrome: a disproportionality analysis . . .
Drug-induced GBS, though less commonly reported, presents significant diagnostic and therapeutic challenges This study investigates the correlation between various medications and the onset of GBS
- SUN-688 Unexpected Consequences: Guillain-Barre Syndrome Following GLP . . .
Discussion: To our knowledge, this is the first reported case of GBS following use of a GLP-1 agonist While GLP-1 agonist medications are generally well tolerated, this case highlights the importance of recognizing potential neurological complications
- Preclinical Immunogenicity of a 6-Valent GBS Glycoconjugate . . . - MDPI
In this study, we present a novel hexavalent GBS vaccine candidate with a unique combination of serotypes (ST)—Ia, Ib, II, III, V, and VII—that could be an efficacious and cost-effective intervention, with the broadest coverage of 99% against circulating serotypes globally
- Immunoglobulin unresponsive Guillain-Barré syndrome: rinse or repeat? A . . .
The strengths of this systematic review are that this is the first and only comprehensive evaluation of treatment options for severely affected GBS patients IVIg is often used as a first-line treatment for GBS, predominantly because of its convenience and availability
- FDA Requires Warning for Guillain-Barré Syndrome in Prescribing . . .
Experts maintain that RSV vaccination benefits outweigh risks for older adults, despite the GBS concerns Continuous monitoring and collaboration among pharmacists, physicians, and public health officials are crucial for vaccine safety
- Drug-Induced Guillain-Barré Syndrome | SpringerLink
This drug was withdrawn from the market in 1983 because of its association with GBS as 10 cases in 200,000 prescriptions indicated that the population exposed to it was 25 times more liable to develop GBS than the unexposed population
- Guillain-Barré syndrome in adults: Treatment and prognosis
The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barré syndrome (GBS), after the authors of early descriptions of the disease
- Guillain–Barré syndrome - Nature Reviews Disease Primers
Guillain–Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy Patients typically develop rapidly progressive weakness and sensory deficits that can result in complete paralysis
|
|
|